The role of BCL‐XL in apoptosis resistance of senescent tumor cells was further supported by studies by Gayle et al. [68] showing that senescent, triple‐negative breast tumor cells induced by bromodomain and extra‐terminal proteins (BET) inhibitors express higher levels of BCL‐XL. Here, BCL2L1 is linked to neoplasm.